Literature DB >> 16799989

Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses.

Simona Urbani1, Barbara Amadei, Paola Fisicaro, Daniela Tola, Alessandra Orlandini, Luca Sacchelli, Cristina Mori, Gabriele Missale, Carlo Ferrari.   

Abstract

A timely, efficient, and coordinated activation of both CD4 and CD8 T cell subsets following HCV infection is believed to be essential for HCV control. However, to what extent a failure of the individual T cell subsets can contribute to the high propensity of HCV to persist is still largely undefined. To address this issue, we analyzed the breadth, vigor, and quality of CD4 and CD8 responses simultaneously with panels of peptides covering the entire HCV sequence or containing the HLA-A2-binding motif, and with recombinant HCV proteins in 16 patients with acute HCV infection by tetramer staining, ELISPOT, and intracellular cytokine staining for interferon gamma, interleukin (IL)-2, IL-4, and IL-10. Our results indicate that at clinical onset, CD8 responses are similarly weak and narrowly focused in both self-limited and chronically evolving infections. At this stage, CD4 responses are deeply impaired in patients with a chronic outcome as they are weak and of narrow specificity, unlike the strong, broad and T helper 1-oriented CD4 responses associated with resolving infections. Only patients able to finally control infection show maturation of CD8 memory sustained by progressive expansion of CD127+ CD8 cells. Thus, a poor CD8 response in the acute stage of infection may enhance the overall probability of chronic viral persistence. In conclusion, the presence of functional CD4 responses represents one of the factors dictating the fate of infection by directly contributing to control of the virus and by promoting maturation of protective memory CD8 responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799989     DOI: 10.1002/hep.21242

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  76 in total

1.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

2.  The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.

Authors:  Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento
Journal:  Immunology       Date:  2017-03-13       Impact factor: 7.397

3.  The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Authors:  Eui-Cheol Shin; Su-Hyung Park; Michelina Nascimbeni; Marian Major; Laura Caggiari; Valli de Re; Stephen M Feinstone; Charles M Rice; Barbara Rehermann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 4.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

5.  Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver.

Authors:  Bertram Bengsch; Hans Christian Spangenberg; Nadine Kersting; Christoph Neumann-Haefelin; Elisabeth Panther; Fritz von Weizsäcker; Hubert E Blum; Hanspeter Pircher; Robert Thimme
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

7.  Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Melissa K Osborn; Kamil Obideen; Mohammad Wehbi; Gordon J Freeman; Jeffrey L Lennox; Kimberly A Workowski; Holly L Hanson; Arash Grakoui
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

Review 10.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.